LINCOCIN INJECTION 300mg/ML

Product Information

Registration Status: Active

LINCOCIN INJECTION 300mg/ML is approved to be sold in Singapore with effective from 1988-08-06. It is marketed by PFIZER PTE LTD, with the registration number of SIN01716P.

This product contains Lincomycin 300mg/ml in the form of INJECTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.

This product is manufactured by PHARMACIA & UPJOHN CO in UNITED STATES.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Lincomycin

Description

An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.

Indication

Lincomycin is an antibiotic used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.

Mechanism of Action

Lincomycin inhibits protein synthesis in susceptible bacteria by binding to the 50 S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible organisms.

Pharmacokinetics

Absorption
Rapidly absorbed from the gastrointestinal tract following oral administration. Approximately 20 to 30% absorbed orally in fasting state; absorption decreased when taken with food.
Distribution
Metabolism
Presumed hepatic, however metabolites have not been fully characterized.
Elimination

Active Ingredient/Synonyms

LCM | Lincomycine | Lincomycin |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank